PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Sahajanand Medical Technologies (SMT)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Six Month Clinical Outcomes of SMTís Supralimus-Sirolimus Eluting Stent Presented at EuroPCR 09 - Six Month Clinical Outcomes of SMTís Supralimus-Sirolimus Eluting Stent with a Biodegradable Polymer (part of the prospective Multicenter E-Series Registry) is presented at EuroPCR 2009
Six Month Clinical Outcomes of SMTís Supralimus-Sirolimus Eluting Stent Presented at EuroPCR 09

 

NewswireToday - /newswire/ - Surat, Gujarat, India, 2009/07/02 - Six Month Clinical Outcomes of SMTís Supralimus-Sirolimus Eluting Stent with a Biodegradable Polymer (part of the prospective Multicenter E-Series Registry) is presented at EuroPCR 2009.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Six months outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry. The dataset demonstrates excellent results in high risk patients with complex coronary lesions, including high procedural success rate (> 97%), and sustained safety.

Presented by Dr. Ricardo A. Costa, of Cardiovascular Research Center, Brazil, Preliminary clinical results at 6 months (60%) from Multicenter E-Series Registry demonstrate clinical effectiveness of Supralimus in preventing revascularization, with only 2% TVR (Target Vessel Revascularization) rate. There were no thrombosis events and no TVR/TLR in the Supralimus treated patientís in-Hospital. The stent thrombosis rate (definite/probable, ARC) up to 6 months was less than 1%.
Out-of Hospital adverse events (N=718) included only 2% Cardiac Death, 0.5% MI (Myocardial infarction) and 4.5% of MACE (Major Cardiac Adverse Event). Thus the preliminary data with the Supralimus-Sirolimus Eluting Stent has shown promising results.

The Study was conducted by Dr. Alexandre Abizaid, Dr. Ricardo Costa and others from Jan 2007 which involved 1181 Patients with 1260 lesions and prospectively enrolled in 50 cities of Brazil, Venezuela and India. The included patients were real world scenario with routine or emergency PCI. Mean age of patients was 64 years & risk factors included 79% Hypertension, 38% Diabetes, 31% Smoker, 23% with Previous MI, 64% with Dyslipidemia, 34% with Previous PCI and 46% with Family History of CAD. Clinical follow was scheduled at 1, 6, 12 and 24 months. Final analysis of this registry is awaited with great hope & promise.

About Sahajanand Medical Technologies
Established in the year 1998, company (smtpl.com) became the first Indigenous Stent Manufacturer in world to have two DES systems in its product portfolio. It is Indiaís largest manufacturing company based on Evidence Based Implantable Medical Devices and Medical Equipments. The products are manufactured conforming to the international quality standards and are offered at the most competitive prices. The Company is ISO 9000 certified & also obtained CE certification for its advanced range of products. This gives assurance of companyís quality consciousness.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sahajanand Medical Technologies (SMT)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Six Month Clinical Outcomes of SMTís Supralimus-Sirolimus Eluting Stent Presented at EuroPCR 09

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: J P Dutta - SahMed.com 
+91-261-245-1451 pr[.]sahmed.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sahajanand Medical Technologies (SMT) securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sahajanand Medical Technologies (SMT) / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroADô Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove
GE Healthcare and HeartFlow Announce Global Cardiovascular Collaboration
Insulin Delivery Devices Market Size to Expand at 7% CAGR through 2020 Says PMR
Intubation Market Significant Profits Estimated to be Generated by 2025 Says Persistence Market Research
PMR Releases Report for Next Generation IV Infusion Pumps Market Impact of Existing and Emerging Market 2017-2025
Medical Tapes Market to Reach US$ 2Bn by 2024 Reports PMR
Global Pyrogen Testing Market Value Expected to Increase to US$ 1.37 Billion by 2024 Says PMR
Huber Needles Market Expected to Reach US$ 55M by 2024 According to PMR
ZOLL Technologies for Improving CPR Quality to be Showcased at NTI 2017
ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men
Biomarker-based Technologies to Disrupt Conventional Diagnosis in Diabetes Management across the Globe Finds Frost & Sullivan
Agfa Specialty Products Announces the Launch of UNIQOAT

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today ó Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)